Brief: HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab
05/06/2025 24:47
June 5 (Reuters) - HUTCHMED (China) Ltd 0013.HK: NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WITH SINTILIMAB ACCEPTED FOR REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION Source text: ID:nHKS3DXz2 Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))